Company Overview
Cybin D/B/A Helus Pharma functions as a clinical-stage neuropsychiatry company dedicated to developing psychedelic-based therapeutics specifically designed for patients suffering from mental health conditions. The firm is currently advancing CYB003, a deuterated psilocybin analog, which is undergoing phase 3 clinical trials intended to treat major depressive disorder. Operating within the healthcare sector and the biotechnology industry, the company targets the specialized field of mental health treatments utilizing novel chemical compounds. The entity employs a workforce of 50 individuals and maintains a market capitalization of $237.00M, while its annual revenue and sales figures are not disclosed in the available financial data. The market cap of $237.00M indicates that the company is valued as a significant entity within the biotech space, yet the lack of reported revenue highlights that its valuation is driven primarily by its clinical pipeline and potential future commercialization prospects rather than current sales performance.
Financial Health
The company reports a net income of $-123,217,320 and an EBITDA of $-119,248,656 over the trailing twelve-month period, while specific revenue figures are not available for disclosure. The substantial gap between the reported revenue (which is unavailable) and the significant negative net income reveals that the company's cost structure is heavily weighted toward research, development, and clinical trial expenses typical of a pre-revenue biotechnology firm. Free cash flow stands at $-69,987,976, which indicates that the company is burning cash to fund its operations and clinical programs, thereby limiting immediate financial flexibility for external acquisitions or large-scale shareholder returns. All three margin metrics—gross margin, operating margin, and profit margin—are listed at 0.0%, a figure that suggests the company has not yet achieved profitability or that margins are not calculated in the standard manner due to the early stage of its commercialization. Despite these negative earnings, the balance sheet is fortified by $195.13M in cash, whereas debt figures are not listed, and the debt-to-equity ratio is unavailable. This liquidity position suggests the company is not currently leveraged in a manner that would threaten its solvency given its cash reserves. The current ratio is reported at 13.78, indicating a very strong ability to cover short-term obligations with short-term assets, reflecting a conservative approach to working capital management. Return on Equity is -55.9% and Return on Assets is -31.9%, metrics that reveal management is currently deploying capital to generate losses as part of the standard expansion phase for a clinical-stage company rather than generating immediate returns.
Valuation Assessment
The trailing P/E ratio is not available due to the absence of earnings, while the forward P/E is listed at -1.49, a negative figure that implies the market is pricing in future earnings that are expected to turn positive or that the current valuation model relies on non-GAAP measures or forward-looking estimates rather than historical profitability. The difference between the unavailable trailing P/E and the negative forward P/E suggests that the valuation is entirely forward-looking and dependent on the successful outcome of the clinical trials for CYB003 rather than current financial performance. The price-to-book ratio stands at 0.87, indicating that the stock is trading below its book value, which often suggests the market is not assigning a significant premium to the company's intangible assets or clinical pipeline at this moment. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are unavailable or negative (EV/EBITDA at -0.36), suggesting that traditional valuation multiples are not applicable until the company generates revenue and positive cash flow. The 52-week high is $9.83 and the 52-week low is $4.52, meaning the current price sits somewhere within this range, subject to market volatility. The beta value is 0.88, which indicates that the stock's price volatility is slightly lower than the broader market, suggesting it may be less sensitive to general market swings than a beta of 1.0 would imply.
Growth & Income
Revenue growth and earnings growth rates are both listed as not available, which implies that the company is in a phase where historical year-over-year growth metrics are not yet meaningful due to the lack of consistent commercial sales. Since the growth rates are unavailable, it is impossible to determine if earnings are growing faster or slower than revenue, but the focus remains on the development of the therapeutic product rather than scaling sales. The company does not pay dividends, as the dividend yield is not available and the payout ratio is 0.0%, meaning the firm reinvests all available capital and earnings back into the business to fund its clinical trials and operational expansion. Consequently, the overall growth and income profile is characterized by a complete lack of current income generation and a reliance on capital markets for funding growth, with all financial resources directed toward achieving clinical milestones rather than providing shareholder distributions.